March Biosciences

March is a clinical-stage cell therapy company developing next-generation CAR-T therapies for T-cell malignancies. Its lead asset, a CAR-T therapy targeting CD5, is entering Phase II clinical trials for T-cell lymphoma and leukemia. The treatment has demonstrated complete responses in highly relapsed/refractory patients while overcoming key challenges, including fratricide during expansion and severe immunodepletion, that have historically limited CAR-T development for these diseases.